Close Menu

NEW YORK – A group of researchers at Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences has identified a chromosomal instability biomarker in circulating tumor cells (CTCs) that it believes can potentially help guide treatment for metastatic castration-resistant prostate cancer (mCRPC).

San Diego-based Epic Sciences may also pursue the development of a multi-marker panel integrating the new biomarker along with others for predicting prostate cancer treatment response, depending on the results of future validation studies.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.